FDAapproval83% confidence
FDA Drug Competition Action Plan | Improving the efficiency of the generic drug development, review, and approval process
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Pfizer.
Regulatory Analysis
By clarifying FDA’s regulatory expectations for new entrants and experienced drug developers alike, FDA is supporting prospective generic drug developers and improving the overall quality of ANDAs submitted to the Agency for approval.
Supporting Context
- Therapeutic area
- Hematology · Hemophilia A/B
- Sub-indication
- General
Related signal: European Commission Approves Pfizer’s HYMPAVZI for Hemophilia A and B Treatment